1-800-567-8911 or
604-682-5050
(Telephone interpreting in over 150 languages available)
Sofosbuvir + velpatasvir + voxilaprevir
Trade Name:
Vosevi
Manufacturer/Distributor:
Gilead Sciences Canada
Classification:
Antiviral agent for treatment of chronic hepatitis C infection
ATC Class:
J05AP56 - sofosbuvir + velpatasvir + voxilaprevir
Status:
active
Notice of Compliance (yyyy/mm/dd):
2017/08/16
Date Marketed in Canada (yyyy/mm/dd):
2017/09/18
Presentation:
Tablet: 400 mg sofosbuvir + 100 mg velpatasvir + 100 mg voxilaprevir. DIN: 02467542
Comments:
This combination product is indicated for the treatment of chronic hepatitis C virus (HCV) infection in adult patients, without cirrhosis or with compensated cirrhosis, who have: genotype 1, 2, 3, 4, 5, or 6 infection and have previously been treated with an HCV regimen containing an NS5A inhibitor; OR genotype 1, 2, 3, or 4 infection and have been previously treated with an HCV regimen containing sofosbuvir without an NS5A inhibitor.
Back to:
Drug Product Listings 
